The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis.
Hari Prasad Ravipati
No relevant relationships to disclose
Jonathan L. Kaufman
Consultant or Advisory Role - Celgene; Janssen; Millennium; Novartis; Onyx
Research Funding - Celgene; Merck
Amelia A. Langston
No relevant relationships to disclose
Lawrence Boise
Consultant or Advisory Role - Onyx
Christopher Flowers
Consultant or Advisory Role - Allos Therapeutics; Celgene; Genentech/Roche (U); Millennium (U); OptumRx; Seattle Genetics; Spectrum Pharmaceuticals
Research Funding - Millennium; Novartis; Spectrum Pharmaceuticals
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis; Onyx; Sanofi
Ajay K. Nooka
No relevant relationships to disclose